NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
Status:
Completed
Trial end date:
2020-08-19
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate the safety of the study drug, NU-0129,
based on Spherical Nucleic Acid (SNA) platform when infused in patients with recurrent
glioblastoma multiforme or gliosarcoma. The SNA consists of nucleic acids arranged on the
surface of a small spherical gold nanoparticle. This is a first-in-human trial to determine
the safety of NU-0129. NU-0129 can cross the blood brain barrier (a filtering mechanism that
carry blood to the brain). Once within the tumor, the nucleic acid component is able to
target a gene called Bcl2L12 that is present in glioblastoma multiforme, and is associated
with tumor growth. This gene prevents tumor cells from apoptosis, which is the process of
programmed cell death, thus promoting tumor growth. Researchers think that targeting the
Bcl2L12 gene with NU-0129 will help stop cancer cells from growing.